Switch Therapeutics

About Switch Therapeutics

Switch Therapeutics is an emerging precision neuroscience biotechnology company focused on developing biomarker-gated, innovative genetic medicines to transform the treatment of central nervous system (CNS) diseases.

Products & Services

Conditionally Activated siRNA (CASi) Platform:A proprietary platform combining advantageous properties of single and double-stranded RNA in a single molecule, enabling efficient self-delivery, uptake, potent and durable knockdown, and the ability to target specific cell types and states for treating CNS diseases.

Specialties

RNAi Therapies Central Nervous System (CNS) Diseases Precision Medicine Conditionally Activated siRNA (CASi) Technology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 52000000 MR: - FA: $52 million FAN: 52000000	D: 2023-03-14 FD: 2023-03-14	10 investors

Series A Latest

2023-03-14

$52.0M

10 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Dee Datta

Co-Founder & CEO

C

Charles Allerson

CTO

M

Michael Wolfe

Senior Vice President, Finance & Operations

C

Craig Blanchette

Senior Vice President, Research

B

Brandi Simpson

Senior Vice President, Business Development

A

Anindya Bhattacharya

Vice President, Head of Neuroscience

View 32 more team members with Pro

Unlock Full Team Directory

Recent News